GLP1R and type 2 diabetes mellitus: On par with the abovementioned antihypertensive drugs, we believe that there is no reason supported by evidence to contraindicate, or vice versa, overpromote GLP1 RAs for managing people with T2D; however, there is an urgent need to determine whether their use can influence the clinical course of COVID-19.